Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 15/07/2025 am IST			5-day change	1st Jan Change
799.34 ^USD	+0.80%		+3.42%	+3.54%

11/07	Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	RE
11/07	FDA May Fast Track Drug Reviews for Lower US Prices	MT

Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May

Published on 17/06/2025 at 21:21

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Eli Lilly and Company

Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	11/07	RE
FDA May Fast Track Drug Reviews for Lower US Prices	11/07	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	11/07	MT
Guggenheim Adjusts Eli Lilly and Co.'s Price Target to $942 From $936, Keeps Buy Rating	11/07	MT
Wall Street Waits to Hear the Numbers	11/07
Eli Lilly and Co (India) with Association of Physicians of India announces launch of API - Obesity Gurukul - statement	11/07	RE
Morgan Stanley Adjusts Price Target on Eli Lilly to $1,135 From $1,133, Maintains Overweight Rating	10/07	MT
Sector Update: Health Care Stocks Higher Late Afternoon	10/07	MT
Sector Update: Health Care	10/07	MT
Öhman Health and New Technology Fund Rises 3.9% in June - Camurus Surges After Eli Lilly Partnership	09/07	FW
Eli Lilly Seen Benefiting From Higher Zepbound Sales in Q2, BofA Says	09/07	MT
Eli Lilly: new recommended dosage for Kisunla	09/07	CF
Eli Lilly and Company Announces FDA Approves Updated Label for Lilly's Kisunla (donanemab-azbt) with New Dosing in Early Symptomatic Alzheimer's Disease	09/07	CI
Eli Lilly Gets FDA Approval for Updated Kisunla Dosing for Alzheimer's	09/07	MT
Eli Lilly FDA approves updated label for Kisunla	09/07	RE
US FDA approves gradual dosing for Lilly Alzheimer's drug	09/07	RE
Trump says pharmaceutical tariffs could reach 200%	09/07	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Sector Update: Tech	08/07	MT
Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	07/07	MT
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
How Novo Nordisk misread the US market for its weight loss sensation	02/07	RE
Novo Nordisk Executives Ignored Warnings Against Wegovy Launch	01/07	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

47,000

Sector

Pharmaceuticals

Calendar

07/08 - Q2 2025 Earnings Release

More about the company